BRIEF-Janssen Research & Development reports final Phase 2 data for ibrutinib By: Reuters: Company News December 06, 2016 at 10:57 AM EST * Phase 2 ibrutinib study in cGVHD showed complete or partial response in up to 2/3 of steroid dependent/refractory patients Read More >> Related Stocks: AbbVie Johnson & Johnson